By blocking the shared receptor component for IL-4 and IL-13, dupilumab improves upper and lower airway outcome measures in patients with severe CRSwNP and comorbid asthma, as reported by the body of evidence [26–30]. Here, IL4 is linked to chronic rhinosinusitis with nasal polyps.